Lifespan.io – Join Us: Become a Lifespan Hero!
We are building public awareness and access to innovative treatments for controlling aging and age-related diseases!
- 48% Funded
- $2,449 per month
Related Organizations
Campaign List
Introducing the Public Longevity Group: Building the Future of Public Trust
Building the first public sentiment analysis engine to unlock public trust in longevity.
- 104% Funded
- $104,395 Funded
- campaign
complete
Pearl: Participatory Evaluation of Aging with Rapamycin for Longevity
The first large-scale placebo-controlled clinical trial to determine the effects of Rapamycin on human longevity.
- 243% Funded
- $182,838 Funded
- campaign
complete
MitoMouse: SENS Transgenic Mouse Project
Creating a transgenic mouse demonstrating the rescue of Mitochondrial DNA mutations in mammals. We will express the mitochondrial ATP8 gene from the nucleus as...
- 155% Funded
- $77,625 Funded
- campaign
complete
Can NMN Increase Longevity?
The first long-term lifespan study in mice involving supplementation with NMN, a precursor of NAD+ metabolism, which has been shown to reduce aging markers and...
- 250% Funded
- $75,285 Funded
- campaign
complete
MouseAge: Visual Biomarker for Mouse Aging
Using AI and Computer Vision Techniques to Determine Age and Assess the Effect of Therapies Against Aging in Mice, Increasing the Pace of Research.
- 130% Funded
- $19,508 Funded
- campaign
complete
AgeMeter: Functional Age Biomarkers
Developing a diagnostic system to measure human functional age in comparison to chronological age, and assist in the assessment of anti-aging therapeutics.
- 100% Funded
- $30,061 Funded
- campaign
complete
CellAge: Targeting Senescent Cells With Synthetic Biology
Designing better systems for detection and safe removal of dysfunctional “senescent” cells to improve health and treat age-related diseases.
- 171% Funded
- $34,215 Funded
- campaign
complete
OncoSENS Control ALT Delete Cancer
High-throughput screening of a library of diverse drugs to find treatments for ‘ALT’ cancers, those which rely on Alternative Lengthening of Telomeres.
- 120% Funded
- $72,002 Funded
- campaign
complete
The Major Mouse Testing Program
Testing a new class of compounds, Senolytics, on their ability to extend healthy lifespan by clearing out dysfunctional cells in the body.
- 115% Funded
- $52,075 Funded
- campaign
complete
Articles from this author
October 30, 2026
In a new study, late-life treatment with a three-element senolytic vaccine led to lower senescence markers and a 12% increase in median lifespan in female B6 mice. However, short-lived controls complicate the picture [1]. Helping the immune system kill “zombie cells” Cellular SenescenceAs your body ages, more of your cells become senescent. Senescent cells do...
October 29, 2026
In Aging Cell, researchers have described how increasing fibroblast growth factor 13 (FGF13) in astrocytes reduces aging throughout the bodies of mice. A factor from a well-known family FGFs are signaling molecules that share structural and functional commonalities and play crucial roles in biology, including neural function [1]. Some of these molecules are secreted, and...
October 28, 2026
A recent study identified SRSF1, an RNA-processing and splicing factor, as a molecule with geroprotective potential. Inducing SRSF1 expression rejuvenated human cells in vitro, extended lifespan, and significantly reduced frailty in mice [1]. Alternative approaches Differentiated cells have the capacity to rejuvenate if an appropriate molecular environment is provided. The best-known factors that enable cellular...
October 27, 2026
One of the oldest and biggest longevity conferences moved this year across the Atlantic, from Copenhagen to Boston. The new location brought ARDD close to several important longevity hubs and might have contributed to this edition’s practical, entrepreneurial, and forward-oriented spirit. We have already reported on the unprecedented panel where FDA named longevity a priority....
October 27, 2026
Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, announced interim data from its Phase 1 clinical trial of ER-100 in three participants with open angle glaucoma (OAG). The data demonstrated that a single intravitreal administration along with daily oral doxycycline was well-tolerated through Day 56 in all...
October 26, 2026
Researchers are developing biomedical repair therapies to address multiple age-related diseases at once, yet they are forced to put them through regulatory pathways built for single-disease drugs. The result is delay, duplication, and unnecessary cost precisely when speed matters the most. The single-disease-indication trap Current regulation still treats age-related diseases as if they were a...